Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data

Chodavadia, Parth; Jacobs, Corbin; Wang, Frances; Havrilesky, Laura J.; Chino, Junzo; Suneja, Gita

doi:10.1016/j.ygyno.2019.09.017

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subgroup analysis of Chodavadia et al, chemoradiotherapy was found to be associated with improved overall survival rates compared with radiotherapy alone for patients with high-intermediate and high-risk stage IB endometrial carcinomas. However, no overall survival benefits were identified for stages IA or II endometrial carcinomas (enrolling 852 patients with stage IA–II uterine serous carcinoma) 22 . The results of a study by de Boer et al, in which 105 patients with stage IA–III uterine serous carcinoma were enrolled, showed that a significant improvement in overall survival was observed with chemoradiotherapy compared with radiotherapy alone.…”

Section: Discussionmentioning

confidence: 99%

An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma

Li,

Yi,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The aim of the present study was to investigate whether a combination of chemotherapy plus radiotherapy was able to increase the overall survival rates compared with chemotherapy alone in stage IB-III uterine serous carcinoma. A total of 1096 patients (593 who had not received radiotherapy, and 503 who had) with primary stage IB-III uterine serous carcinoma who underwent surgery and received chemotherapy were included in the present study. The Kaplan–Meier method and Log-Rank tests showed that radiotherapy did not increase 5-year overall survival rates compared with the no-radiotherapy groups (52.3 cf. 50.8%, respectively; P = 0.641). Cox regression analysis subsequently corroborated that radiotherapy did not affect the 5-year overall survival rate (P = 0.635). Patients who were aged ≥ 60 years had a higher mortality rate [hazard ratio (HR), 1.712; 95% confidence interval (95% CI), 1.385–2.117; P < 0.05]. The 5-year overall survival rates were found to be lower in the groups where the regional lymph nodes had not been removed (HR 0.645; 95% CI 0.508–0.821; P < 0.05). Chemotherapy plus radiotherapy was found to not be associated with improved 5-year overall survival rates. However, chemotherapy may be a better treatment option for patients with primary stage IB-III uterine serous carcinoma who have undergone surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma

Li,

Yi,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Similar RT use trends have also been reported in America using the National Cancer Database (NCDB). Parth A. Chodavadia et al evaluated the off-study use of RT and found the largest increase in VBT + CT use in 2009 and in the year GOG-249 was initiated [ 13 ]. Sara J. Zakem et al demonstrated that the utilization rate of VBT alone was higher than that of pelvic EBRT.…”

Section: Discussionmentioning

confidence: 99%

Utilization Trend and Comparison of Different Radiotherapy Modes for Patients with Early-Stage High-Intermediate-Risk Endometrial Cancer: A Real-World, Multi-Institutional Study

Ren

Zou

Wang

et al. 2022

Cancers

View full text Add to dashboard Cite

This study aimed to compare the outcomes of RT modalities among patients who met different HIR criteria based on multicentric real-world data over 15 years. The enrolled patients, who were diagnosed with FIGO I-II EC from 13 medical institutes and treated with hysterectomy and RT, were reclassified into HIR groups according to the criteria of GOG-249, PORTEC-2, and ESTRO-ESMO-ESGO, respectively. The trends in RT modes utilization were reviewed using the Man-Kendall test. The rate of VBT alone increased from zero in 2005 to 50% in 2015, which showed a significant upward trend (p < 0.05), while the rate of EBRT + VBT utilization declined from 87.5% to around 25% from 2005 to 2015 (p > 0.05). There were no significant differences in OS, DFS, LRFS, and DMFS between VBT alone and EBRT ± VBT in three HIR cohorts. Subgroup analyses in the GOG-249 HIR cohort showed that EBRT ± VBT had higher 5-year DFS, DMFS, and LRFS than VBT alone for patients without lymph node dissection (p < 0.05). Thus, VBT could be regarded as a standard adjuvant radiation modality for HIR patients. EBRT should be administrated to selected HIR patients who meet the GOG-249 criteria and did not undergo lymph node dissection.

show abstract

“…There are few studies in the literature concerning the administration schedule of adjuvant treatments for EC, most of which report results with respect to advanced stages, excluding intermediate–high- and high-risk EC [ 16 , 17 , 21 , 22 , 23 ]. In contrast, our study includes both initial stages (27.6% FIGO I–II stages) and advanced stages (72.4% FIGO III-IV stages) at high risk of recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, performing RT before CT may lead to progression outside the radiation fields. Therefore, the “sandwich” schedule can be considered as a possible alternative [ 16 , 17 , 21 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

The “Sandwich” Schedule: A Well-Tolerated Adjuvant Treatment Both in Intermediate–High- and High-Risk Endometrial Cancer

et al. 2022

View full text Add to dashboard Cite

(1) Background: In intermediate–high- and high-risk endometrial cancer (EC), radiotherapy (RT) and chemotherapy (CT) play a basic role. However, there is controversy regarding the optimal timing of their combination. The “sandwich” schedule involves adjuvant CT followed by RT and subsequent CT. The aim of this study is to assess the tolerability and efficacy of the “sandwich” schedule. (2) Methods: A retrospective study was conducted in two gynecological oncology units in Torino, Italy, from 01/01/2003 until 31/12/2021. Intermediate–high- and high-risk patients with available clinical data were included. Compliance with treatment, CT and RT toxicities, disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) were analyzed. (3) Results: A total of 118 patients were selected: 27,1% FIGO I-II stages and 72.9% III-IV. Most of the patients (75.4%) received a carboplatin–paclitaxel combination, and as much as 94.9% of CT cycles were completed. Chemotherapy-related G3-4 toxicities were detected in 5.3% of the patients, almost half of which were hematological. Grade 2 gastrointestinal and genitourinary toxicities were reported in 8.4% and 4.2% of cases, respectively. With a median follow-up of 46 months, DFS was 77.6%, CSS was 70% and 5-year OS was 54%. (4) Conclusions: The “sandwich” schedule for CT and RT combination is an effective adjuvant treatment with low toxicity both in intermediate–high- and high-risk EC.

show abstract

Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data

Cited by 9 publications

References 23 publications

An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma

An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma

Utilization Trend and Comparison of Different Radiotherapy Modes for Patients with Early-Stage High-Intermediate-Risk Endometrial Cancer: A Real-World, Multi-Institutional Study

The “Sandwich” Schedule: A Well-Tolerated Adjuvant Treatment Both in Intermediate–High- and High-Risk Endometrial Cancer

Contact Info

Product

Resources

About